Thursday, 02 April 2020

Cord Blood expands in China

08 February 2013 | News | By BioSpectrum Bureau

China Cord Blood (CCB) effective equity interest in Shandong Province Qilu Stem Cells Engineering increased from 19.9 percent to 24 percent

China Cord Blood (CCB) effective equity interest in Shandong Province Qilu Stem Cells Engineering increased from 19.9 percent to 24 percent

Singapore: China Cord Blood (CCB), which is the first and largest cord blood banking operator in China, highlighted that it has completed the previously announced transaction with Cordlife Services, a subsidiary of CCB's strategic affiliate. Cordlife is a cord blood and tissue banking services provider listed on the Australian Securities Exchange (ASX).

As a result of the transaction, CCB's effective equity interest in Shandong Province Qilu Stem Cells Engineering, the operator of the Shandong Cord Blood Bank, has increased from 19.9 percent-to-24 percent, further extending the company's presence in the Shandong market. The transaction was first announced on December 6, 2012.

 

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account